

Alaska Medical Assistance DUR Committee Meeting Minutes

Friday, September 17th, 2021

Meeting was held Telephonically due to COVID-19. 1:00PM

Drug Utilization Review Committee Attendees

Members Present	Non Members Present
Erin Narus, PharmD (DHSS)	Umang Patel, PharmD (Magellan)
Charles Semling, PharmD (DHSS)	Ryan Ruggles, PharmD, MSHI (Magellan)
Charles Ryan, MD	
Robert Carlson, MD	
Barb Piromalli, DO	
Jonathon Harrison, PharmD	Members Absent
Keri McCutcheon, RPh	Dr. Heath McAnally, MD

Call to order at 1:01 PM.

Review of Agenda

Charles Semling went over the Agenda for the committee members.

Review of minutes from April 2021

Charles Semling asked the committee if they had any changes to the minutes. The date of the previous meeting minutes needed to be fixed to January 2021.

Motion to approve by Charles Ryan.

Second by Barb Piromalli.

Minutes approved.

Overview of Medicaid Prescription and Cost Trends

Charles Semling went through the detail of the program trend snapshot.

Cost was up by ~3 million dollars. Contributing factors was more users, and expensive drugs.

The committee reviewed the graphs for biggest positive and negative contributing drugs.

Per member per month and per utilizer per month trends were presented. The state expects the trend line to continue on the same upward trajectory.

Amount paid per therapeutic class was reviewed and looks to be as expected. Amount paid per drug was presented. Notable changes include Lantus fell due to other options; Ozempic, Jardiance and Skyrizi were newly added; and Vivitrol moved higher in the list.

Prospective Drug Utilization Review/Clinical Topic Areas

New Prescription Medications (Interim PA List – 6 month review)

Interim PA list was short for this meeting. Charles Semling presented the logic for these medications and conditions that they treat. The committee agreed that the list seemed reasonable.

Barb Piromalli moved to approve

Second by Charles Ryan.

Max Units

The committee reviewed the maximum unit list.

For ondansetron tabs and odt, Charles Semling proposed to increase the quantity limit to 30 units per day. Overutilization was discussed, but the committee decided that the safety was proven, likely no abuse or diversion. It was agreed to increase the quantity limit.

New Quantity limit additions, Jardiance, Qelbree, Bystolic, Viibryd, Ozempic, Semglee, Latuda, Rexulti, Vraylar, Adhansia XR, Adzenys XR, Aptensio XR, Azastarys, Jorney PM

Barb Piromalli moved to approve the changes as presented.

Charles Ryan seconded.

New Prior Authorizations, Quantity Limits, Edits

Lupkynis criteria was presented along with a summary of the ICER report.

Keri McCutcheon moved to approve.

Charles Ryan seconded.

Isturisa criteria was presented.

Charles Ryan moved to approve.

Barb Piromalli seconded.

Aduhelm criteria was presented along with a summary of the ICER report.

The committee commented on the appropriateness of the approval criteria mirroring the study inclusion criteria. Point 2 was discussed regarding removing the term geriatric psychologist and leaving it as neurologist consult. Committee suggested to rereview in the future. State will review prior to April meeting, and if there is utilization will bring to that meeting, otherwise will wait until the following September meeting.

Charles Ryan moved to approve with the proposed change.

Bob Carlson seconded.

Orilissa, Oriahnn, Myfembree criteria was presented.

It is noted that this criteria is just adding Myfembree.
Charles Ryan moved to approve as written.
Barb Piromalli seconded.

Vancocin criteria was presented.

It is an old criteria, and the state does not believe that the criteria is no longer applicable, and recommends to retire the criteria.

Barb Piromalli moved to approve.

Keri McCutcheon seconded.

Opioid Report

Charles Semling presented the opioid use tables. The committee pointed out some nuances in attempting to interpret the data. We will get answers to the inclusion of hospice, oncology, and long term care patients. Also, we will attempt to identify the shift in patients over time.

ICD-10 Compliance report was presented to the committee.

Charles Semling pointed out some nuances of certain pharmacies and old pharmacies are to be removed from the report.

ICD-10 Compliance report for Stimulants was presented. It was acknowledged how well the pharmacies are doing.

Benzodiazepine, Opioid, and Antipsychotic overlap comparison

Opioid and Z-Drug Overlap over time

The trends including the date where edits were created were presented. All of the classes decreased over time, and it was noted that quetiapine was the most common antipsychotic combo.

Charles Semling presented to add an edit to add an edit requiring the pharmacist to override and approve the use of the combination of z-drug and opioid combination or discuss with the prescriber in order to bill the claim.

The committee approved.

Safety Reports

Charles Semling presented the FDA safety report regarding Ocaliva. FDA is continuing to monitor for potential heart problems.

Charles Semling presented the FDA safety report regarding Alcohol-Based Sanitizers. FDA is continuing to monitor for potential heart problems.

Charles Semling presented the FDA safety report regarding Statins. FDA is continuing to monitor for potential heart problems.

FAERS Reports

FAERS Report was presented, and reviewed by the committee.

Post meeting comments

Charles Semling expressed thanks to the committee members for their thoughts and comments.

End of Public Meeting

Adjournment 3:18 p.m.

Next meeting date November 19th, 2021.